Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Guardant Health, Inc.

https://www.guardanthealth.com/

Latest From Guardant Health, Inc.

JPM 2024: ‘Economic Engine:’ Genomics News Abound From Exact, Guardant And Veracyte

The three genomics players all announced preliminary results prior to speaking, and all had more news to add about their recent success and their plans to grow the demand for cancer diagnostics.

Medical Device Diagnostics

News We’re Watching: Activist Investor Causes Kerfuffle At Nevro, Lifespin Launches Antibiotic Dx, And More

Medtech Insight's News We're Watching highlights medtech industry news developments that you may have missed over the last few weeks. Last week, EndoQuest closed a $42m round to support its endoluminal surgery system, Intuitive Ventures closed a $150m round, Noah Surgical announced the first biopsy procedures with its Galaxy technology in Asia, the FDA cleared Smileyscope's VR system to reduce needle anxiety, and Guardant will collaborate with Cancer Research UK.

News We're Watching Companies

News We’re Watching: More Class I Recalls, FDA Expands TAP, Guardant Appeals Patent Verdict, And More

This week, the US FDA labelled several recalls class I, approved an at-home diagnostic for chlamydia and gonorrhea, and announced the expansion of its TAP pilot program. Guardant Health also announced it would appeal a verdict in a patent suit against the company and AdvaMed voiced its continued support for pending breakthrough device legislation.

News We're Watching FDA

Companies Find Growth Opportunities In Maturing Colorectal Cancer Blood-Based Screening Market

Companies making blood-based cancer screening tests face a number of barriers to full market entry but getting a foothold of any kind can be the start of a path towards greater ultimate uptake.

Market Intelligence Strategy
See All

Company Information

  • Industry
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • Other Names / Subsidiaries
    • Guardant
UsernamePublicRestriction

Register